FDA Updates SMA Treatment Dosing - Poll - MDSpire

FDA Updates SMA Treatment Dosing

A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing.

  • By

  • Kathryn Wighton

  • March 30, 2026

  • 2 min

Share

Original Source(s)

FDA Updates SMA Treatment Dosing

  • by Kathryn Wighton

  • March 30, 2026

Related Content

Treatable Pediatric Neuromuscular Disorders

Through a case-based, evidence-driven approach, this Neuroscience Grand Rounds session highlights how clinicians can differentiate among neuromuscular conditions, localize disease processes and identify those disorders where timely treatment can significantly alter disease trajectory.

  • June 19, 2026

  • 1 min
Michael Todinca, M.D., Neuromuscular Neurologist, Joins Baptist Health Miami Neuroscience Institute

Neurologist Michael Todinca, M.D., who specializes in neuromuscular medicine, has joined Baptist Health Miami Neuroscience Institute, part of Baptist Health Brain & Spine Care. 

  • by

  • July 13, 2026

  • 3 min
Early Neurodevelopmental Outcomes in Pediatric Congenital Heart Disease

In a multicenter registry study, genetic diagnoses were associated with substantially lower cognitive, language, and motor scores; while birth weight, surgical timing, hospitalization burden, and caregiver education were also associated with outcomes.